Cancer News
Laura Huppert, MD
Laura Huppert, MD is an accomplished oncologist specializing in the treatment of breast cancer patients across all stages of the disease.
Recent Posts
Pathologic Complete Response: I-SPY2 Trial Insights
Apr 14, 2023 1:40:25 PM / by
Laura Huppert, MD
posted in
ASCO22
,
Breast Cancer
0 Comments
Pathologic Complete Response: How can the I-SPY2 study results benefit patients with HR+ HER2- Breast Cancer? Laura Huppert MD - Synopsis below extracted from the video transcript.
Read More
All posts
Subscribe to Email Updates
Recent
Popular
Categories
Lists by Topic
ASH
(12)
MOASC
(9)
City of Hope
(6)
Interview
(5)
Lymphoma
(5)
ASCO22
(4)
B-cell Lymphoma
(3)
Chronic Lymphocytic Leukemia
(3)
Gastrointestinal Malignancies
(3)
Immunotherapy
(3)
Lung Cancer EGFR
(3)
ASCO FCR Guidelines
(2)
Breast Cancer
(2)
Kidney Cancer
(2)
Ravi Salgia
(2)
Renal Cell Carcinoma
(2)
Thoracic Oncology
(2)
UC Irvine
(2)
Acute Myeloid Leukemia
(1)
Antibody Conjugates
(1)
CAR T-cell
(1)
Ethnic Minorities
(1)
Follicular Lymphoma
(1)
HER2 low
(1)
Health Inequity
(1)
Mehrdad Mobasher
(1)
Mosunetuzumab
(1)
Multiple Myeloma
(1)
Nataliya Mar
(1)
Odronextamab
(1)
Oncocyte
(1)
Penn Medicine
(1)
SABCS
(1)
Small Cell Lung Cancer
(1)
Small Lymphocytic Leukemia
(1)
Trial Eligibility
(1)
UCSF
(1)
Urothelial Cancer
(1)
Yuan Yuan
(1)
Zanubrutinib
(1)
belzutifan
(1)
idecabtagene vicleucel
(1)
see all
Posts by Topic
ASH
(12)
MOASC
(9)
City of Hope
(6)
Interview
(5)
Lymphoma
(5)
ASCO22
(4)
B-cell Lymphoma
(3)
Chronic Lymphocytic Leukemia
(3)
Gastrointestinal Malignancies
(3)
Immunotherapy
(3)
Lung Cancer EGFR
(3)
ASCO FCR Guidelines
(2)
Breast Cancer
(2)
Kidney Cancer
(2)
Ravi Salgia
(2)
Renal Cell Carcinoma
(2)
Thoracic Oncology
(2)
UC Irvine
(2)
Acute Myeloid Leukemia
(1)
Antibody Conjugates
(1)
CAR T-cell
(1)
Ethnic Minorities
(1)
Follicular Lymphoma
(1)
HER2 low
(1)
Health Inequity
(1)
Mehrdad Mobasher
(1)
Mosunetuzumab
(1)
Multiple Myeloma
(1)
Nataliya Mar
(1)
Odronextamab
(1)
Oncocyte
(1)
Penn Medicine
(1)
SABCS
(1)
Small Cell Lung Cancer
(1)
Small Lymphocytic Leukemia
(1)
Trial Eligibility
(1)
UCSF
(1)
Urothelial Cancer
(1)
Yuan Yuan
(1)
Zanubrutinib
(1)
belzutifan
(1)
idecabtagene vicleucel
(1)
See all
Recent Posts
